Glenmark gains 2% after launching Zita Piomet for type 2 diabetes – Moneycontrol

My Account
Follow us on:
Powered By
Find & Invest in bonds issued by top corporates, PSU Banks, NBFCs, and much more. Invest as low as 10,000 and earn better returns than FD
Invest Now
Find safe & high-yielding bonds for your buck. Discover the right bonds meeting your investment amount & investment horizon
Invest Now
Powered By
Diversify your portfolio by investing in Global brands.
Invest Now
Pre-configured baskets of stocks & ETFs that you can invest
in with a single click. Developed by hedge funds, global
asset management companies, experienced wealth
management firms and portfolio managers.
Invest Now

AMBAREESH BALIGA
Fundamental, Stock Ideas, Multibaggers & Insights
Subscribe
CK NARAYAN
Stock & Index F&O Trading Calls & Market Analysis
Subscribe
SUDARSHAN SUKHANI
Technical Call, Trading Calls & Insights
Subscribe
T GNANASEKAR
Commodity Trading Calls & Market Analysis
Subscribe
MECKLAI FINANCIALS
Currency Derivatives Trading Calls & Insights
Subscribe
SHUBHAM AGARWAL
Options Trading Advice and Market Analysis
Subscribe
MARKET SMITH INDIA
Model portfolios, Investment Ideas, Guru Screens and Much More
Subscribe
TraderSmith
Proprietary system driven Rule Based Trading calls
Subscribe


Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas
Subscribe
Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas
Explore
STOCK REPORTS BY THOMSON REUTERS
Details stock report and investment recommendation
Subscribe
POWER YOUR TRADE
Technical and Commodity Calls
Subscribe
INVESTMENT WATCH
Set price, volume and news alerts
Subscribe
STOCKAXIS EMERGING MARKET LEADERS
15-20 High Growth Stocks primed for price jumps
Subscribe
Shares of Glenmark Pharmaceuticals Ltd jumped 2.6 percent on December 21 after the company said it has launched Zita-Piomet for type 2 diabetes.
The stock hit a high of Rs 419 a share. At 10.25am, the scrip was trading at Rs 419 a share on BSE, up 2.5 percent from its previous close.
The drug contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation and help to improve glycemic control among adults with High HbA1ci and high insulin resistance.
” Being a leader in diabetes therapy in the country, we are proud to introduce Zita®‐PioMet, India’s first triple fixed dose combination for high insulin‐resistant type 2 diabetes. The innovative, effective, and affordable drug will help improve the glycemic control among adult patients with high HbA1c.” said  Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals Ltd.
The company on December 19 announced that  it had received the final approval from the United States Food and Drug Administration for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, which are used for treating high blood pressure and chest pain.
The capsules are the generic version of Cardene 1 Capsules, 20 mg and 30 mg, of Chiesi USA, Inc.
Glenmark’s current portfolio consists of 178 products authorised for distribution in the US marketplace and 46 ANDAs pending approval with the US FDA.
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
You are already a Moneycontrol Pro user.

source